Innogenetics: Appointment of Corporate Broker

Gent (Belgium), 10 January, 2004

The Board of Innogenetics is pleased to announce the appointment of Code Securities Limited as Corporate Broker and Financial Advisor to the Company.

About Innogenetics
Innogenetics is an international biopharmaceutical company building parallel businesses in the areas of specialty diagnostics and therapeutic vaccines. In 2003, total revenues increased to €73 million, with a profitable Specialty Diagnostics Division. Its Diagnostics Division develops a large number of specialty products covering three areas: infectious diseases (hepatitis C, hepatitis B, and HIV), genetic testing (HLA tissue typing and cystic fibrosis), and neurodegeneration (Alzheimer’s disease). In its Therapeutics Division, Innogenetics focuses on the development of therapeutic vaccines to address unmet medical needs in the field of infectious diseases, with two compounds now in clinical trials (hepatitis C in phase 2 and hepatitis B in phase 1). With a strong commercially oriented management team and distinctive dual business model, Innogenetics provides a low-risk biotech investment with potentially high returns.

Founded in 1985, Innogenetics is listed on Euronext Brussels. Innogenetics’ headquarters are in Gent, Belgium, with sales affiliates in the United States, Germany, France, Spain, and Italy. Innogenetics employs 590 people worldwide and has a market capitalization of approximately €400 million.

About Code Securities
Code Securities is a European investment banking firm providing a full range of advisory, fundraising and corporate broking services for companies and investors in the life sciences and medtech sectors. Code Securities is authorised and regulated by the UK Financial Services Authority.

For further information, please contact:
Jean-Christophe Donck
Director Corporate Communications
Phone + 32 9 329 1701
Fax + 32 9 329 1908
jeandon@innogenetics
www.innogenetics.com